Peer-influenced content. Sources you trust. No registration required. This is HCN.

Cancer Therapy AdvisorMetastatic Breast Cancer: Phase 3 Studies Herald More Options for Metastatic Breast Cancer

Presented at SABCS 2021, the EMERALD Study of elacastrant and the PHOEBE Trial of pyrotinib showed a better than doubling of 12-month PFS with the first agent, and an improvement in both OS and PFT with the second agent. And the results of the DESTINY-Breast03 study have been called “practice changing.”

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form